scholarly journals Angptl4 links α-cell proliferation following glucagon receptor inhibition with adipose tissue triglyceride metabolism

2015 ◽  
Vol 112 (50) ◽  
pp. 15498-15503 ◽  
Author(s):  
Danny Ben-Zvi ◽  
Ornella Barrandon ◽  
Stephanie Hadley ◽  
Barak Blum ◽  
Quinn P. Peterson ◽  
...  

Type 2 diabetes is characterized by a reduction in insulin function and an increase in glucagon activity that together result in hyperglycemia. Glucagon receptor antagonists have been developed as drugs for diabetes; however, they often increase glucagon plasma levels and induce the proliferation of glucagon-secreting α-cells. We find that the secreted protein Angiopoietin-like 4 (Angptl4) is up-regulated via Pparγ activation in white adipose tissue and plasma following an acute treatment with a glucagon receptor antagonist. Induction of adipose angptl4 and Angptl4 supplementation promote α-cell proliferation specifically. Finally, glucagon receptor antagonist improves glycemia in diet-induced obese angptl4 knockout mice without increasing glucagon levels or α-cell proliferation, underscoring the importance of this protein. Overall, we demonstrate that triglyceride metabolism in adipose tissue regulates α-cells in the endocrine pancreas.

2017 ◽  
Vol 19 (11) ◽  
pp. 1521-1528 ◽  
Author(s):  
Cristina B. Guzman ◽  
Xiaotian M. Zhang ◽  
Rong Liu ◽  
Arie Regev ◽  
Sudha Shankar ◽  
...  

2017 ◽  
Vol 19 (8) ◽  
pp. 1071-1077 ◽  
Author(s):  
Christof M. Kazda ◽  
Juan Frias ◽  
Irene Foga ◽  
Xuewei Cui ◽  
Cristina B. Guzman ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 73-OR ◽  
Author(s):  
JEREMY PETTUS ◽  
ERIC G. VAJDA ◽  
JAMES PIPKIN ◽  
GRETCHEN WILLIAMSON ◽  
MIRIAM A. ZANGMEISTER ◽  
...  

2021 ◽  
Author(s):  
Sofie Hædersdal ◽  
Asger Lund ◽  
Henrik Maagensen ◽  
Elisabeth Nielsen-Hannerup ◽  
Lærke S Gasbjerg ◽  
...  

Objective: Type 2 diabetes (T2D) pathophysiology includes fasting and postprandial hyperglucagonemia, which has been linked to hyperglycemia via increased endogenous glucose production (EGP). We used a glucagon receptor antagonist (LY2409021) and stable isotope tracer infusions to investigate consequences of hyperglucagonemia in type 2 diabetes. Design: A double-blinded, randomized, placebo-controlled crossover study was conducted. Methods: Ten patients with T2D and ten matched non-diabetic controls underwent two liquid mixed meal tests preceded by single-dose administration of LY2409021 (100 mg) or placebo. Double-tracer technique was used to quantify EGP. Antagonist selectivity towards related incretin receptors was determined in vitro. Results: Compared to placebo, LY2409021 lowered fasting plasma glucose from 9.1 to 7.1 mmol/L in patients and from 5.6 to 5.0 mmol/L in controls (both P<0.001) by mechanisms involving reduction of EGP. Postprandial plasma glucose excursions (baseline-subtracted area under the curve) were unaffected by LY2409021 in patients and increased in controls compared to placebo. Glucagon concentrations more than doubled during glucagon receptor antagonism. The antagonist interfered with both glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, complicating the interpretation of the postprandial data. Conclusions: LY2409021 lowered fasting plasma glucose concentrations but did not improve postprandial glucose tolerance after a meal in patients with T2D and controls. The metabolic consequences of postprandial hyperglucagonemia are difficult to evaluate using LY2409021 because of its antagonizing effects on the incretin receptors.


Sign in / Sign up

Export Citation Format

Share Document